

Special Issue

Biomarkers of Alpha-Synuclein Pathology

Message from the Guest Editor

Alpha-synuclein (a-syn) plays a key role in the pathology of Parkinson's disease (PD), dementia with Lewy bodies (DLB), Multiple system atrophy (MSA), and other diseases. However, we are still short of biomarkers for alpha-synuclein pathology and its progression in living people. There are yet no cures for these diseases and biomarkers that can direct future therapies are urgently needed. This special issue aims to gather studies of potential biomarkers of a-syn pathology in PD, DLB, MSA, and related diseases with emphasis on diagnostic and prognostic value, and the use of non-invasive patient samples.

Guest Editor

Dr. Johannes Lange

Norwegian Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway

Deadline for manuscript submissions

closed (30 June 2023)



NeuroSci

an Open Access Journal
by MDPI

Impact Factor 1.6
Indexed in PubMed



mdpi.com/si/79664

NeuroSci
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
neurosci@mdpi.com

[mdpi.com/journal/
neurosci](https://mdpi.com/journal/neurosci)





NeuroSci

an Open Access Journal
by MDPI

Impact Factor 1.6
Indexed in PubMed



[mdpi.com/journal/
neurosci](https://mdpi.com/journal/neurosci)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Dr. François Ichas

Institut des Maladies Neurodégénératives, CNRS et Université de
Bordeaux, UMR 5293, Bordeaux, France

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid
by authors or their institutions.

High Visibility:

indexed within ESCI (Web of Science), PMC, PubMed,
EBSCO, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is
provided to authors approximately 19.9 days after
submission; acceptance to publication is undertaken in 4.7
days (median values for papers published in this journal in
the second half of 2024).